On September 25th, Dongkook Pharmaceutical announced that it had confirmed the safety and efficacy of its incrementally modified combination drug for benign prostatic hyperplasia (BPH), ‘DKF-313,’ through a Phase III trial.

Based on the positive results, Dongkook Pharmaceutical plans to complete the Phase III trial result report within the year, then apply for its marketing authorizations and release.

DKF-313 is the world’s first combination of dutasteride and tadalafil. According to Dongkook Pharmaceutical, its combo drug has a dual effect of reducing prostate size while improving urinary disorder symptoms from BPH and can bring better treatment effect than single-agent drugs.